MolMed
Автор: Alliance for Regenerative Medicine
Загружено: 2017-10-24
Просмотров: 1442
Описание:
Luca Alberici, Ph.D., Business Development Director
Milan, Italy
(MLM.MI)
MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel cell and gene therapy products. MolMed’s pipeline main products are Zalmoxis® (TK), a cell-based therapy in Phase III in high-risk acute leukemia and granted a Conditional Marketing Authorization by the European Commission, and CAR-CD44v6, an immune gene therapy project potentially effective for many hematological malignancies and several epithelial tumors, currently in preclinical development. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop and validate projects from preclinical to Phase III trials, including scale-up and cGMP manufacturing of retroviral and lentiviral vectors and patient-specific genetically engineered CD34+ or T-cells. MolMed is headquartered in Milan and has two GMP manufacturing facilities in the Milan area. MolMed has been listed on the Milan Stock Exchange managed by Borsa Italiana since 2008. www.molmed.com
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
